Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 433-442

  Sahebkar, Amirhossein ^a,b   Kotani, Kazuhiko ^c   Serban, Corina ^d   Ursoniu, Sorin ^d   Mikhailidis, Dimitri P ^e   Jones, Steven R ^f   Ray, Kausik K ^g,h   Blaha, Michael J ^f   Rysz, Jacek ^g,h   Toth, Peter P ^f,i   Muntner, Paul ^j   Lip, Gregory Y H ^k   Banach, Maciej ^h  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ CGH MEDICAL CENTER   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Endothelial dysfunction; Endothelin 1; Lipophilicity; Statins; Therapy

Indexed keywords

ATORVASTATIN; CERIVASTATIN; ENDOTHELIN 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; LIPID;

ARTICLE; CHRONOTHERAPY; COCHRANE LIBRARY; DATA SYNTHESIS; DOSE RESPONSE; DRUG EFFICACY; EMBASE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCOPUS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEB OF SCIENCE; ADULT; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DYSLIPIDEMIAS; FEMALE; MALE; MIDDLE AGED; ODDS RATIO;

ADULT; AGED; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DYSLIPIDEMIAS; ENDOTHELIN-1; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84936757096     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.022     Document Type: Article

References (66)

1. Negi S., Anand A. Atherosclerotic coronary heart disease epidemiology, classification and management. Cardiovasc. Haematol. Disorders-Drug Targets (Formerly Curr. Drug Targets-Cardiovasc. Hematol. Disord. 2010, 10:257-261.
2. Mordi I., Tzemos N. Is reversal of endothelial dysfunction still an attractive target in modern cardiology?. World J. Cardiol. 2014, 6:824.
3. Piechota M., Banach M., Jacoń A., et al. Natriuretic peptides in cardiovascular diseases. Cell. Mol. Biol. Lett. 2008, 13:155-181.
4. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:338-349.
5. Pernow J., Shemyakin A., Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci. 2012, 91:507-516.
6. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
7. Shimada K., Takahashi M., Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 1994, 269:18275-18278.
8. Irzmanski R., Banach M., Piechota M., et al. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin. Exp. Hypertens. 2007, 29:149-164.
9. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep. Med. Rev. 2003, 7:35-51.
10. Jagroop I.A., Daskalopoulou S.S., Mikhailidis D.P. Endothelin-1 and human platelets. Curr. Vasc. Pharmacol. 2005, 3:393-399.
11. Morawietz H., Duerrschmidt N., Niemann B., et al. Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem. Biophys. Res. Commun. 2001, 284:961-965.
12. Meyers K.E., Sethna C. Endothelin antagonists in hypertension and kidney disease. Pediatr. Nephrol. 2013, 28:711-720.
13. Schaefer R. Lipid management for the prevention of cardiovascular disease. Curr. Pharm. Des. 2011, 17:852-860.
14. Toth P.P. Low-density lipoprotein reduction in high-risk patients: how low do you go?. Curr. Atheroscler. Rep. 2004, 6:348-352.
15. Banach M., Mikhailidis D.P., Kjeldsen S.E., et al. Time for new indications for statins?. Med. Sci. Monit. 2009, 15:MS1-MS5.
16. Banach M., Aronow W.S., Serban C., et al. Lipids, blood pressure and kidney update 2014. Pharmacol. Res. 2015, 95:111-125.
17. Ii M., Losordo D.W. Statins and the endothelium. Vasc. Pharmacol. 2007, 46:1-9.
18. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009, 203:325-330.
19. Sahebkar A., Chew G.T., Watts G.F. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res. 2014, 56:47-66.
20. Hernández-Perera O., Pérez-Sala D., Navarro-Antolín J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Investig. 1998, 101:2711.
21. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
22. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control. Clin. Trials 1996, 17:1-12.
23. Moher D., Cook D., Jadad A., et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol. Assess. Winch. Engl. 1998, 3:i-iv. 1-98.
24. Borenstein M., Hedges L., Higgins J., et al. Comprehensive Meta-analysis Version 2 2005, Biostat, Englewood, NJ, 104-104.
25. Sutton A.J., Abrams K.R., Jones D.R., et al. Methods for Meta-analysis in Medical Research 2000, J. Wiley.
26. Sahebkar A. Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013, 32:188-198.
27. Dupont W.D., Plummer W.D. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials 1998, 19:589-601.
28. Song F., Altman D.G., Glenny A.-M., et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Bmj 2003, 326:472.
29. Bucher H.C., Guyatt G.H., Griffith L.E., et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 1997, 50:683-691.
30. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
31. Abou-Raya A., Abou-Raya S., Helmii M. Statins as immunomodulators in systemic sclerosis. Ann. N. Y. Acad. Sci. 2007, 1110:670-680.
32. Åsberg A., Holdaas H., Jardine A.G., et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin. Transplant. 2003, 17:385-390.
33. Barsuk A.L., VAM, Malinok E.V., Lovtsova L.V., Okrut I.E., Kuzin V.B. The dynamics and interaction of endothelium state and immune status variations in program hemodialysis patients against the background of atorvastatin therapy. Mod. Thechnol. Med. 2013, 5:78-83.
34. Dupuis J., Tardif J.-C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
35. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
36. Lee T.-M., Su S.-F., Tsai C.-H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002, 40:67-73.
37. Lee T., Chen C., Shen H., et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin. Sci. 2009, 116:497-505.
38. Lee T.-M., Lin M.-S., Tsai C.-H., et al. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptor blockers. Kidney Int. 2005, 68:779-787.
39. Lewandowski J., Siński M., Bidiuk J., et al. Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia. Hypertens. Res. 2010, 33:1038-1043.
40. Li J.-J., Fang C.-H., Wang C., et al. Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 concentrations in patients with stable angina. Clin. Chim. acta 2005, 354:205-208.
41. Nakamura T., Ushiyama C., Hirokawa K., et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am. J. Nephrol. 2001, 21:449-454.
42. Mozaffarian D., Minami E., Letterer R.A., et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am. J. Cardiol. 2005, 96:1699-1704.
43. Tehrani S., Mobarrez F., Lins P.-E., et al. Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes. Diabetes Vasc. Dis. Res. 2013, 10:483-488.
44. Usharani P., Mateen A.A., Naidu M.U.R., et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs R. D. 2008, 9:243-250.
45. Economides P.A., Caselli A., Tiani E., et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J. Clin. Endocrinol. Metabol. 2004, 89:740-747.
46. Usharani P., Mateen A., Naidu M., et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs R. D. 2008, 9:243-250.
47. Tanner F.C., Boulanger C.M., Lüscher T.F. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Seminars Thromb. Hemost. 1992, 167-175.
48. Ludman A., Venugopal V., Yellon D.M., et al. Statins and cardioprotection-more than just lipid lowering?. Pharmacol. Ther. 2009, 122:30-43.
49. Mihos C.G., Pineda A.M., Santana O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol. Res. 2014, 88:12-19.
50. Kohan D.E. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1997, 29:2-26.
51. Battistini B., D'Orleans-Juste P., Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab. Investig. J. Tech. Methods Pathol. 1993, 68:600.
52. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Fail 2007, 13:1-7.
53. Qu H.Y., Xiao Y.W., Jiang G.H., et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm. Res. 2009, 26:958-964.
54. Sakamoto T., Kojima S., Ogawa H., et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ. J. Off. J. Jpn. Circ. Soc. 2007, 71:1348-1353.
55. Fujita M., Yamazaki T., Hayashi D., et al. Pleiotropic effects of statins on cardiovascular events in the Japanese coronary artery disease study. Int. J. Cardiol. 2008, 129:294-296.
56. Kai T., Arima S., Taniyama Y., et al. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki adiponectin interventional (KAI) Study. Clin. Exp. Hypertens. 2008, 30:530-540.
57. Tsutamoto T., Yamaji M., Kawahara C., et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur. J. heart Fail. 2009, 11:1195-1201.
58. Kim M.C., Ahn Y., Jang S.Y., et al. Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction. Korean J. Intern. Med. 2011, 26:294-303.
59. Murrow J.R., Sher S., Ali S., et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J. Clin. Lipidol. 2012, 6:42-49.
60. Bailey K.M., Romaine S.P., Jackson B.M., et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 study. Circ. Cardiovasc Genet. 2010, 3:276-285.
61. Mason R.P., Walter M.F., Day C.A., et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am. J. Cardiol. 2005, 96:11-23.
62. Tomizawa A., Hattori Y., Suzuki K., et al. Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin. Int. J. Cardiol. 2010, 144:108-109.
63. Nezasa K., Higaki K., Matsumura T., et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 2002, 30:1158-1163.
64. Liu G., Zheng X.-X., Xu Y.-L., et al. Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart, Lung Circulation 2014, 23:970-977.
65. Sahebkar A., Watts G.F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther. 2013, 35:1082-1098.
66. Dragan S., Serban M.-C., Banach M. Proprotein convertase Subtilisin/Kexin 9 inhibitors an emerging lipid-lowering therapy?. J. Cardiovasc. Pharmacol. Ther. 2015, 20:157-168.